NOVEL THERAPIES FOR INFLAMMATORY AND FIBROTIC DISEASES THAT DEPEND ON
PROLONGED MIF ACTIVITY
OUR SCIENCE
Apaxen is developing innovative treatments for patients with diseases that depend on chronically increased activity of MIF.
More than 30 years of research have shown that prolonged high levels of MIF are driving chronic inflammation, tissue remodelling and fibrosis.
By targeting MIF, a cytokine/growth factor like protein, Apaxen’s platform allows for the development of novel treatments for many inflammatory, fibrosis and inflammaging-related diseases
PIPELINE
Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 Inflammasome activation and MIF.
LATEST NEWS & PUBLICATIONS
Apaxen appoints Graham K. Dixon as Chairman and prepares for clinical testing of its lead inflammasome inhibitor
Gosselies, Belgium, July 18, 2022 – Apaxen S.A., a privately-held biotechnology company, developingnovel next generation NLRP3 inflammasome inhibitor drugs for treatment of chronic inflammatoryand auto-immune…
Belgian biotech Apaxen appoints Bart Wuurman as CEO
Gosselies, Belgium, November 12, 2020 – Apaxen S.A., a privately-held preclinical stage biotechnology company, developing novel oral drugs for chronic inflammatory diseases, with a primary…
PR – Apaxen raises €3.3 million in Series A Financing
Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension.
